Eli Lilly and Company (LILY34.SA)
| Previous close | 129.09 |
| Open | 127.27 |
| Bid | 125.00 x 0 |
| Ask | 126.59 x 0 |
| Day's range | 123.52 - 127.27 |
| 52-week range | 69.45 - 137.15 |
| Volume | |
| Avg. volume | 14,191 |
| Market cap | 3.734T |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 108.68 |
| EPS (TTM) | 1.16 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | 0.60 (0.48%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
Barrons.comAmazon Stock Is on a Roll. Here’s Why It’s on This Firm’s ‘Best Ideas List.’
Amazon reported strong first-quarter results, with revenue and operating income ahead of expectations. The company delivered operating income of $15.3 billion, above consensus of $11.3 billion, while reporting better-than-expected growth in both Amazon Web Services (+17.2% year over year versus Street +15%) and advertising (+24.3% Y/Y versus Street +23.5%). Amazon has now reported operating income above the high end of its guidance range for five consecutive quarters, and the company has a number of drivers for further margin expansion in place, including continued cost efficiencies within its fulfillment network as well as the ongoing mix shift toward higher-margin AWS and advertising revenue.
Yahoo FinanceAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
ZacksAmgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
